Immunohistochemical analysis of the impact of ischemic change in benign prostatic hyperplasia
ConclusionIn patients with response to ischemic changes of the prostate, HIF-1α expression could be confirmed, and the expression of the androgen receptor was significantly lower in these patients. Chronic ischemic damage in the prostate can progress to a condition that is refractory to pharmacologic therapy. Chronic ischemic damage, which can progress to refractory phase to pharmacologic therapy, is correlated with the hormonal status of prostate.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Benign Prostatic Hyperplasia | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Hormones | Hypertension | Obesity | Pathology | Smokers